Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Sep;87(17):6649-53.
doi: 10.1073/pnas.87.17.6649.

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL

Affiliations

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL

M A Kelliher et al. Proc Natl Acad Sci U S A. 1990 Sep.

Erratum in

  • Proc Natl Acad Sci U S A 1990 Nov;87(22):9072

Abstract

The v-abl gene in Abelson virus induces pre-B-cell lymphoma in mice while the BCR/ABL oncogene is associated with chronic myelogenous leukemia and some cases of acute lymphocytic leukemia in humans. Understanding the mechanisms by which these oncogenes affect various cell types has been hampered by a paucity of experimental systems that reproduce the range of biological effects associated with them. We have developed an experimental system in which murine hematopoietic stem cell populations are infected with either v-abl or BCR/ABL retroviruses and are used to reconstitute lethally irradiated mice. Irrespective of the form of activated abl, greater than 90% of the animals reconstituted with such cells develop tumors. About 50% of them develop a myeloproliferative syndrome that shares several features with the chronic phase of chronic myelogenous leukemia; the remaining animals succumb to pre-B-cell lymphomas. The myeloproliferative syndrome is characterized by large numbers of clonally derived, infected myeloid cells. This model will allow study of the mechanism by which activated abl genes affect hematopoietic precursors in chronic myelogenous leukemia. Furthermore, our results demonstrate that introduction of an activated abl gene into the appropriate target cell, not the structure of the gene, is the major determinant in myeloid cell specificity.

PubMed Disclaimer

References

    1. Cell. 1988 Jun 17;53(6):857-67 - PubMed
    1. N Engl J Med. 1988 Oct 13;319(15):990-8 - PubMed
    1. Mol Cell Biol. 1988 Oct;8(10):4079-87 - PubMed
    1. Adv Virus Res. 1988;35:39-81 - PubMed
    1. J Virol. 1989 May;63(5):1989-94 - PubMed

Publication types

MeSH terms

LinkOut - more resources